查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1612743

癌症疼痛治療市場：按藥物類型、給藥途徑、應用和最終用途分類 - 全球預測 2025-2030

Cancer Pain Management Market by Drug Type (Nerve Blockers, Non-Opioids, Opioids), Route of Administration (Oral, Parental), Application, End-Use - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 197 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年癌症疼痛治療市場價值為74.2億美元，預計到2024年將達到78.6億美元，複合年成長率為6.09%，預計到2030年將達到112.3億美元。

癌症疼痛管理產業涵蓋多種旨在緩解癌症患者疼痛的治療方法和技術。此範圍包括鴉片類藥物、非類固醇消炎劑和輔助性治療等藥物治療，以及針灸、物理治療和神經調節等非藥物治療。癌症疼痛管理的需要源於伴隨疾病及其治療並影響患者生活品質的嚴重的、通常使人衰弱的疼痛。疼痛管理方案的應用超越了安寧療護的範疇，並記錄了患者在癌症治療各階段的生活品質和功能能力的提升。最終用途範圍廣泛，包括醫院、門診手術中心、專科診所和居家照護機構。癌症發病率上升、疼痛管理技術的進步以及患者意識的提高和提高生活品質的需求對市場成長產生了重大影響。

主要市場統計
基準年[2023] 74.2億美元
預測年份 [2024] 78.6億美元
預測年份 [2030] 112.3億美元
複合年成長率（%） 6.09%

關鍵的成長要素包括技術進步和開發更準確、更有效緩解疼痛的新療法，以及有利的政府措施和對醫療基礎設施的投資。新興市場存在潛在的機會，這些市場獲得有效疼痛管理的機會正在改善，綜合疼痛管理方法的採用也在增加。抓住這些機會的研究包括投資創新研究以及擴大與醫療保健提供者的夥伴關係，以提供全面的疼痛管理解決方案。然而，該市場面臨監管挑戰、與先進治療相關的高成本以及限制基於鴉片類藥物的管理策略的鴉片類藥物危機等限制。在低收入和中等收入國家提供個人化疼痛管理解決方案的進入障礙和複雜性也帶來了挑戰。

創新和研究應優先考慮整合個人化醫療、非鴉片類藥物替代品和心理支持的整體方法。透過專注於這些細分市場，公司可以提高業務成長和市場差異化。市場的本質是動態的和多學科的，需要不斷適應並將新的見解整合到綜合癌症治療策略中。癌症疼痛管理市場的相關人員可以透過適應不斷變化的患者需求和法律規範，有效應對這一重要醫療保健領域的各種挑戰和機會。

市場動態：揭示快速發展的癌痛管理市場的關鍵市場洞察

供需的動態交互作用正在改變癌症疼痛治療市場。透過了解這些不斷變化的市場動態，公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險，同時消費行為及其對製造成本的影響以及對採購趨勢的影響。

  • 市場促進因素
    • 全球慢性疼痛和文明病的盛行率不斷上升
    • 老年人口的增加和對疼痛緩解治療的需求
  • 市場限制因素
    • 產品召回問題
  • 市場機會
    • 持續的產品開發活動並增加了 FDA 的新產品核可
    • 政府資助支持癌症疼痛治療
  • 市場問題
    • 與癌症疼痛治療藥物相關的副作用

波特五力：駕馭癌痛治療市場的策略工具

波特的五力框架是了解市場競爭格局的重要工具。波特的五力框架描述了評估公司競爭和探索策略機會的清晰方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢，解決弱點，避免潛在的挑戰，確保更強大的市場地位。

PESTLE分析：了解癌症疼痛治療市場的外在影響

外部宏觀環境因素在塑造癌痛治療市場的績效動態發揮著至關重要的作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素，公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化，並為他們做出積極主動的決策做好準備。

市場佔有率分析：了解癌症疼痛治療市場的競爭格局

癌症疼痛管理市場的詳細市場佔有率分析可以對供應商的表現進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、細分和整合的趨勢，為供應商提供了製定策略決策所需的洞察力，使他們能夠在日益激烈的競爭中佔有一席之地。

FPNV 定位矩陣：癌症疼痛管理市場供應商的績效評估

FPNV 定位矩陣是評估癌痛管理市場供應商的重要工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商，從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商，並確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析與建議：繪製癌痛管理市場的成功之路

對於旨在加強其在全球市場的影響力的公司來說，對癌痛治療市場的策略分析至關重要。透過審查關鍵資源、能力和績效指標，公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰，利用新的商機並取得長期成功。

該報告對涵蓋關鍵焦點細分市場的市場進行了全面分析。

1. 市場滲透率：詳細檢視當前市場環境，主要企業的廣泛資料，評估其在市場中的影響力和整體影響力。

2. 市場開拓：辨識新興市場的成長機會，評估現有細分市場的擴張潛力，並提供未來成長的策略藍圖。

3. 市場多元化：分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報：徹底分析競爭格局，檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新：重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題，以幫助相關人員做出明智的決策。

1.目前的市場規模和未來的成長預測是多少？

2. 哪些產品和地區提供最佳投資機會？

3.塑造市場的關鍵技術趨勢和監管影響是什麼？

4.主要廠商的市場佔有率和競爭地位如何？

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼？

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 世界各地慢性疼痛和文明病的盛行率正在上升
      • 老年人數量不斷增加，需要減輕疼痛的治療方法
    • 抑制因素
      • 與產品召回相關的問題
    • 機會
      • 持續的產品開發活動和 FDA 對新產品的核准增加
      • 政府資助支持癌症疼痛治療
    • 任務
      • 與癌症疼痛治療藥物相關的副作用
  • 市場區隔分析
    • 藥物類型：擴大鴉片類藥物治療癌症疼痛的範圍
    • 給藥途徑：口服藥物擴大用於癌症疼痛治療
    • 應用：乳癌癌痛管理解決方案的普及
    • 最終用途：醫院中癌症鎮痛藥的使用增加
  • 波特五力分析
  • PESTEL分析
    • 政治
    • 經濟
    • 社會
    • 科技
    • 法律
    • 環境

第6章癌痛治療市場：依藥物類型

  • 介紹
  • 阻斷劑
  • 非鴉片類藥物
    • 乙醯胺酚
    • 非類固醇消炎劑(NSAID)
  • 鴉片類藥物
    • Fentanyl
    • 氫可酮

第7章癌症疼痛治療市場：依給藥途徑

  • 介紹
  • 口服
  • 母親和孩子

第8章癌痛治療市場：依應用分類

  • 介紹
  • 血癌
  • 乳癌
  • 大腸直腸癌
  • 肺癌
  • 攝護腺癌

第9章癌痛治療市場：依最終用途分類

  • 介紹
  • 居家醫療
  • 醫院
  • 專科診所

第10章美洲癌痛治療市場

  • 介紹
  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章亞太地區癌症疼痛治療市場

  • 介紹
  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲的癌症疼痛治療市場

  • 介紹
  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • FDA核准非鴉片類止痛藥用於治療輕度至中度疼痛
    • Nevro (NVRO) 最新發布客製化慢性疼痛治療
    • 伊史蒂夫和美敦力合作滿足癌症疼痛患者的需求
  • 戰略分析和建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Aegis Therapeutics, LLC
  • Aptinyx Inc.
  • Astellas Pharma Inc.
  • Bausch Health Companies Inc.
  • Baxter International Inc.
  • Bayer AG
  • Biogen Inc.
  • Boehringer Ingelheim International GmbH
  • Eisai Co., Ltd.
  • Eli Lilly and Company
  • Glaxosmithkline PLC
  • Grunenthal Group
  • Johnson & Johnson Services, Inc.
  • Merck & Co. Inc.
  • Novartis AG
  • Pfizer Inc.
  • Regeneron Pharmaceuticals Inc.
  • Sanofi SA
  • Scilex Pharmaceuticals
  • Teva Pharmaceutical Industries Ltd.
  • Trevena Inc.
Product Code: MRR-144C638C8F7B

The Cancer Pain Management Market was valued at USD 7.42 billion in 2023, expected to reach USD 7.86 billion in 2024, and is projected to grow at a CAGR of 6.09%, to USD 11.23 billion by 2030.

The Cancer Pain Management industry encompasses a wide range of treatments and technologies aimed at alleviating pain in individuals with cancer. This scope includes pharmacological treatments such as opioids, NSAIDs, and adjuvant therapies, along with non-pharmacological methods like acupuncture, physiotherapy, and neuromodulation. The necessity for cancer pain management arises from the severe, often debilitating pain that can accompany the disease and its treatments, impacting patients' quality of life. The application of pain management options extends beyond palliative care, offering enhanced life quality and functional capabilities for patients throughout various cancer treatment stages. End-use scopes are broad, including hospitals, ambulatory surgical centers, specialty clinics, and home care settings. Market growth is heavily influenced by the rising prevalence of cancer, advancements in pain management technologies, and increasing patient awareness and demand for quality of life improvements.

KEY MARKET STATISTICS
Base Year [2023] USD 7.42 billion
Estimated Year [2024] USD 7.86 billion
Forecast Year [2030] USD 11.23 billion
CAGR (%) 6.09%

Key growth factors include technological advancements and the development of new therapeutics aimed at more precise and effective pain relief, along with favorable government initiatives and investments in healthcare infrastructure. Potential opportunities lie in emerging markets where access to effective pain management is improving and the adoption of integrative pain management approaches is increasing. Recommendations to capture these opportunities involve investing in innovative research and expanding partnerships with healthcare providers for comprehensive pain management solutions. However, the market faces limitations including regulatory challenges, high costs associated with advanced therapies, and the opioid crisis, which limits opioid-based management strategies. Challenges also stem from barriers to access in low and middle-income countries and the complexity of achieving personalized pain management solutions.

Innovation and research should prioritize personalized medicine, non-opioid alternatives, and holistic approaches integrating psychological support. By focusing on these areas, companies can enhance business growth and market differentiation. The nature of the market is dynamic and multidisciplinary, requiring continuous adaptation and integration of novel insights into comprehensive cancer care strategies. By aligning with evolving patient needs and regulatory frameworks, stakeholders in the cancer pain management market can effectively address the diverse challenges and opportunities within this critical healthcare segment.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cancer Pain Management Market

The Cancer Pain Management Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic pain and lifestyle disorders worldwide
    • Increasing geriatric population and need for pain-reducing therapies
  • Market Restraints
    • Issues associated with product recalls
  • Market Opportunities
    • Ongoing product development activities and rising FDA approvals of new products
    • Government funding supporting cancer pain treatments
  • Market Challenges
    • Adverse effects associated with cancer pain management drugs

Porter's Five Forces: A Strategic Tool for Navigating the Cancer Pain Management Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cancer Pain Management Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cancer Pain Management Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cancer Pain Management Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cancer Pain Management Market

A detailed market share analysis in the Cancer Pain Management Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cancer Pain Management Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cancer Pain Management Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cancer Pain Management Market

A strategic analysis of the Cancer Pain Management Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cancer Pain Management Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Aegis Therapeutics, LLC, Aptinyx Inc., Astellas Pharma Inc., Bausch Health Companies Inc., Baxter International Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Eisai Co., Ltd., Eli Lilly and Company, Glaxosmithkline PLC, Grunenthal Group, Johnson & Johnson Services, Inc., Merck & Co. Inc., Novartis AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Sanofi SA, Scilex Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Trevena Inc..

Market Segmentation & Coverage

This research report categorizes the Cancer Pain Management Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Drug Type, market is studied across Nerve Blockers, Non-Opioids, and Opioids. The Non-Opioids is further studied across Acetaminophen and Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). The Opioids is further studied across Fentanyl and Morphine.
  • Based on Route of Administration, market is studied across Oral and Parental.
  • Based on Application, market is studied across Blood Cancer, Breast Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
  • Based on End-Use, market is studied across Home care, Hospitals, and Specialty Clinics.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic pain and lifestyle disorders worldwide
      • 5.1.1.2. Increasing geriatric population and need for pain-reducing therapies
    • 5.1.2. Restraints
      • 5.1.2.1. Issues associated with product recalls
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing product development activities and rising FDA approvals of new products
      • 5.1.3.2. Government funding supporting cancer pain treatments
    • 5.1.4. Challenges
      • 5.1.4.1. Adverse effects associated with cancer pain management drugs
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Drug Type: Growing applicability of opioids to treat cancer pain
    • 5.2.2. Route of Administration: Growing availability of oral medications for cancer pain management
    • 5.2.3. Application: Emerging penetration of cancer pain management solutions for breast cancer
    • 5.2.4. End-Use: Elevating usage of cancer pain drugs in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cancer Pain Management Market, by Drug Type

  • 6.1. Introduction
  • 6.2. Nerve Blockers
  • 6.3. Non-Opioids
    • 6.3.1. Acetaminophen
    • 6.3.2. Non-Steroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.4. Opioids
    • 6.4.1. Fentanyl
    • 6.4.2. Morphine

7. Cancer Pain Management Market, by Route of Administration

  • 7.1. Introduction
  • 7.2. Oral
  • 7.3. Parental

8. Cancer Pain Management Market, by Application

  • 8.1. Introduction
  • 8.2. Blood Cancer
  • 8.3. Breast Cancer
  • 8.4. Colorectal Cancer
  • 8.5. Lung Cancer
  • 8.6. Prostate Cancer

9. Cancer Pain Management Market, by End-Use

  • 9.1. Introduction
  • 9.2. Home care
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Cancer Pain Management Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cancer Pain Management Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cancer Pain Management Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. FDA Approves Non-Opioid Painkiller for Mild-to-Moderate Pain
    • 13.3.2. Nevro's (NVRO) Latest Launch to Customize Chronic Pain Treatment
    • 13.3.3. Esteve and Medtronic are Collaborating to Address Cancer Pain Patients' Needs
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Aegis Therapeutics, LLC
  • 4. Aptinyx Inc.
  • 5. Astellas Pharma Inc.
  • 6. Bausch Health Companies Inc.
  • 7. Baxter International Inc.
  • 8. Bayer AG
  • 9. Biogen Inc.
  • 10. Boehringer Ingelheim International GmbH
  • 11. Eisai Co., Ltd.
  • 12. Eli Lilly and Company
  • 13. Glaxosmithkline PLC
  • 14. Grunenthal Group
  • 15. Johnson & Johnson Services, Inc.
  • 16. Merck & Co. Inc.
  • 17. Novartis AG
  • 18. Pfizer Inc.
  • 19. Regeneron Pharmaceuticals Inc.
  • 20. Sanofi SA
  • 21. Scilex Pharmaceuticals
  • 22. Teva Pharmaceutical Industries Ltd.
  • 23. Trevena Inc.

LIST OF FIGURES

  • FIGURE 1. CANCER PAIN MANAGEMENT MARKET RESEARCH PROCESS
  • FIGURE 2. CANCER PAIN MANAGEMENT MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CANCER PAIN MANAGEMENT MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CANCER PAIN MANAGEMENT MARKET DYNAMICS
  • TABLE 7. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NERVE BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ACETAMINOPHEN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-STEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY FENTANYL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY MORPHINE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PARENTAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BLOOD CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOME CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CANCER PAIN MANAGEMENT MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 32. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 33. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 38. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 39. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 40. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 43. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 44. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 45. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 46. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 49. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 51. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 52. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 55. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 57. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 58. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 61. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 63. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 64. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES CANCER PAIN MANAGEMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 68. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 69. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 70. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 71. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 75. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 77. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 78. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 81. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 83. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 84. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 87. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 89. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 90. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 93. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 95. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 96. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 99. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 101. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 102. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 105. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 106. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 107. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 108. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 111. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 112. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 113. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 114. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 117. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 118. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 119. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 120. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 123. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 124. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 125. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 126. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 129. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 130. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 131. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 132. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 135. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 136. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 137. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 138. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 141. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 142. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 143. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 144. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 147. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 148. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 149. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 150. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 154. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 155. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 156. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 157. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 160. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 161. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 162. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 163. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 166. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 167. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 168. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 169. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 172. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 174. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 175. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 178. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 179. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 180. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 181. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 184. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 185. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 186. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 187. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 190. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 191. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 192. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 193. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 196. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 198. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 199. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 202. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 203. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 204. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 205. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 208. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 209. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 210. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 211. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 214. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 215. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 216. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 217. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 220. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 221. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 222. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 223. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 226. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 227. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 228. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 229. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 232. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 233. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 234. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 235. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 238. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 239. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 244. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 245. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 246. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 247. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 250. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 251. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 252. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 253. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 256. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 257. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 258. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 259. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 262. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 263. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 264. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 265. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 268. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 269. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 270. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 271. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY NON-OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY OPIOIDS, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM CANCER PAIN MANAGEMENT MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
  • TABLE 280. CANCER PAIN MANAGEMENT MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 281. CANCER PAIN MANAGEMENT MARKET, FPNV POSITIONING MATRIX, 2023